Pharma Journalist -

Chugai Pharmaceutical announced that the U.S. Food and Drugs Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) and granted Priority Review for…
Read More...

Hookipa Biotech AG and Gilead Science announced that they have entered into a research collaboration and license agreement that grants Gilead exclusive rights to Hookipa’s TheraT and…
Read More...

InflaRx, a biopharmaceutical company developing innovative therapeutics to treat life-threatening inflammatory diseases by targeting the complement system, a key component of the innate…
Read More...

Sensei Biotherapeutics announced the publication of data from the company’s multi-center Phase 1 clinical trial to assess safety and immunogenicity of SNS-301 (formerly PAN-301) in…
Read More...

SMi Reports: Internationally recognized biobanks sign up for 8th annual BioBanking conference, taking place in just 1 week in London. With just a week left until the 8th Annual…
Read More...

Virpax Pharmaceuticals signed a technology license agreement with LipoCure to develop pain management products using its liposome drug delivery technology. The first investigational…
Read More...

Mylan and Biocon announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's Fulphila (pegfilgrastim-jmbd), a biosimilar to Neulasta (pegfilgrastim), co-developed…
Read More...

SMi Group reports: fresh off the press - official agenda for Orphan Drugs and Rare Diseases taking place on 17 - 18 October in London   Patients with rare diseases cannot continue to…
Read More...

Merck announced interim results from Cohort A of KEYNOTE-427, a Phase 2 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as first-line treatment for advanced clear cell renal cell…
Read More...

Novartis announced positive results from the third Phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer. MONALEESA-3 showed Kisqali plus fulvestrant…
Read More...